Detalles del proyecto
| Estado | Activo |
|---|---|
| Fecha de inicio/Fecha fin | 6/16/22 → 4/3/26 |
Financiación
- Vertex Pharmaceuticals Inc: 240.095,00 US$
A Phase 3, Open-Label Study Evaluating the Longterm Safety and Efficacy of VX-121 Combination Therapy in Subjects with Cystic Fibrosis
- Wurth, Mark (PI)
- Anstead, Michael (CoI)
- Danov, Zoran (Former PI)